BioMarin reports positive phase 3 trial results for VOXZOGO in hypochondroplasia

May 20, 2026 4:20 PM

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO (vosoritide) in children with hypochondroplasia met ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found